公开(公告)号：US20180030045A1

公开(公告)日：2018-02-01

申请号：US15670904

申请日：2017-08-07

Applicant: EISAI R&D MANAGEMENT CO., LTD.

Inventor： J. Eric CARLSON ,  Hans HANSEN ,  Lynn HAWKINS ,  Sally ISHIZAKA ,  Matthew MACKEY ,  Shawn SCHILLER ,  Chikako OGAWA ,  Heather DAVIS ,  Atsushi ENDO

IPC: C07D417/14 ,  C07D413/04 ,  C07D401/10 ,  C07D401/14 ,  C07D471/10 ,  C07D487/10 ,  C07D471/04 ,  C07D215/48 ,  C12Q1/68 ,  G01N33/50 ,  C07D451/04 ,  C07D487/04 ,  C07D493/10 ,  C07D413/14 ,  C07D403/14

CPC classification number: C07D417/14 ,  C07B2200/07 ,  C07D215/48 ,  C07D401/10 ,  C07D401/14 ,  C07D403/14 ,  C07D413/04 ,  C07D413/14 ,  C07D451/04 ,  C07D471/04 ,  C07D471/10 ,  C07D487/04 ,  C07D487/10 ,  C07D493/10 ,  C12Q1/6897 ,  G01N33/5023 ,  G01N33/5047

Abstract: Embodiments of the disclosure relate to selectively substituted quinoline compounds that act as antagonists or inhibitors for Toll-like receptors 7 and/or 8, and their use in pharmaceutical compositions effective for treatment of systemic lupus erythematosus (SLE) and lupus nephritis.